Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris.
Details for the presentations are as follows:
Session: VEGF Related and Other Retinal Indications
Title: Optimising the treatment of retinal disease
Presenter: of Outlook Therapeutics
Date and Time: Wednesday, September 3, 2025, 16:10 PM CEST / 10:10 AM EDT
For more information about this event, please visit .
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to optimize the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
